Building Your Toolkit: How to Operationalize FDA Guidance on Diversity

Understand the key points of recent FDA guidance to improve diversity in trials and learn actionable strategies to enroll underrepresented patients

14

November

  • 3PM London / 10AM New York
  • Free

Why attend?

The FDA recently finalized guidance to promote diversity and equity within clinical trials. In this webinar, we discuss how this recent FDA guidance supports patient optionality in clinical trials, especially for underrepresented populations. Join Stephanie Hitchcock, Director of Project Management at PCM Trials and Kris Booth, Director of Strategic Partnerships at EmVenio Research (a PCM Trials company) to:

 

  • Identify actionable strategies for integrating FDA guidance into clinical trial designs to achieve diversity and innovation goals.
  • Explore the potential impact of FDA guidance on future clinical trials, with an emphasis on patient-centricity and inclusivity.

 

Speakers

Select a speaker to learn more

Back
Kris Booth
Director, Strategic Partnerships, EmVenio Research

Kris Booth is the Director of Strategic Partnerships and is responsible for aligning the strategic relationships between CROs, Sponsors, and EmVenio Research. He also assists in the reviewing and implementing of commercial processes in coordination with site operations. Mr. Booth joined EmVenio Research in 2024 with a decade of experience in clinical trial project management and partner relations.

Next speaker
Back
Stephanie Hitchcock
Director of Project Management, PCM Trials

Stephanie Hitchcock is an Director of Project Management at PCM Trials. Stephanie specializes in adapting trial designs for mobile visit services. She is passionate about expanding the use of high-quality, patient-centric models to drive clinical development. Stephanie is an expert in establishing logistics and procedures on a global scale for complex visit schedules and expanding the scope of what mobile visits can support globally.

Next speaker

Enquiry